A comparison of rosoxacin with ampicillin and probenecid in the treatment of uncomplicated gonorrhea.
Rosoxacin, a beta-lactamase-resistant, pyridyl quinolone derivative with in vitro activity against Neisseria gonorrhoeae, was compared to an oral regimen of ampicillin plus probenecid for the treatment of uncomplicated gonococcal infection. Fifty-seven patients were evaluated for the effectiveness of the two antibiotics. Thirty (97%) of 31 patients receiving rosoxacin were cured of their infection as were 25 (96%) of 26 patients who received the oral regimen of ampicillin plus probenecid. Both drug regimens were associated with a significant number of side effects. Of the ampicillin-treated group, 29% had diarrhea and/or abdominal cramping. Of the rosoxacin-treated patients, 52% had reactions classified as central nervous system effects; these included headaches, dizziness, euphoria, and drowsiness.
D042462:4-Quinolones; D000293:Adolescent; D000328:Adult; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011339:Probenecid / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones
D042462:4-Quinolones; D000890:Anti-Infective Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin; D000667:Ampicillin; D011339:Probenecid